#Eli Lilly#diabetes#Dexcom#pharmaceutical#pharmaceutical

Dexcom partners with Eli Lilly surrounding its ongoing diabetes management

Becoming the first company to introduce the first biosynthetic ‘human’ insulin with recombinant DNA technology in the 1980s, Eli Lilly continues to be a...

Catherine Sturman
|Nov 24|magazine5 min read

Becoming the first company to introduce the first biosynthetic ‘human’ insulin with recombinant DNA technology in the 1980s, Eli Lilly continues to be a leader in diabetes management.

The company has recently partnered with Dexcom to strengthen its position within the diabetes market. Dexcom will link its smart insulin delivery devices, such as its continuous glucose monitoring (CGM) with Lilly’s Connected Diabetes Ecosystem to strengthen both companies position and fight off growing competition in this space.

Through the Connected Diabetes Ecosystem, both parties will aim to provide a comprehensive solution. Devices such as CGM, smart-pens and insulin pumps, drugs, apps and other analytical tools will be aimed at improving outcomes. Clinical trials are expected to begin by the end of 2017.

Related stories

“Lilly’s Connected Diabetes Ecosystem promises to drive a significant step forward in diabetes management. As technology converges in our industry, we believe that connected systems will become the standard of care over time,” explained Kevin Sayer, President and CEO of Dexcom.

“By combining devices, drugs and technology, we can deliver solutions that adapt to each person’s unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers.”

“The Connected Diabetes Ecosystem relies not only on Lilly’s core diabetes expertise, but also the strength of our key partners such as Dexcom,” commented Enrique Conterno, President of Lilly Diabetes and Lilly USA.

“Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes.”